HOECHST MARION ROUSSEL MUST CHOOSE BETWEEN TRENTAL OR BERAPROST UNDER FTC AGREEMENT; BIOVAIL WILL HAVE RIGHT-OF-REFERENCE TO DILTIAZEM PHARM/TOX DATA
Executive Summary
Hoechst Marion Roussel must divest either Trental (pentoxifylline) or a research program for beraprost to preserve competition in the intermittent claudication market, according to a proposed consent agreement with the Federal Trade Commission approving the merger of Hoechst and Marion Merrell Dow announced Sept. 18.